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Abstract 62 
 63 
Objective:  Disorders caused by impairments in the parathyroid 64 
hormone (PTH) signalling pathway are historically classified under the 65 
term pseudohypoparathyroidism (PHP), that encompasses rare, related 66 
but highly heterogeneous diseases with demonstrated (epi)genetic 67 
causes. The actual classification is based on the presence or absence of 68 
specific clinical and biochemical signs together with an in vivo response 69 
to exogenous PTH and the results of an in vitro assay to measure Gsa 70 
protein activity. However, this classification disregards other related 71 
diseases like acrodysostosis (ACRDYS) or Progressive Osseous 72 
Heteroplasia (POH), as well as recent findings of clinical and 73 
genetic/epigenetic background of the different subtypes. 74 
Therefore, the EuroPHP network decided to develop a new classification 75 
that encompasses all disorders with impairments in PTH and/or PTHrP 76 
cAMP-mediated pathway. 77 
Design and Methods: Extensive review of the literature was performed. 78 
Several meetings were organised to discuss about a new, more effective 79 
and accurate way to describe disorders caused by abnormalities of the 80 
PTH/PTHrP signalling pathway.  81 
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Results and Conclusions: After determining the major and minor criteria 82 
to be considered for the diagnosis of these disorders, we proposed to 83 
group them under the term «inactivating PTH/PTHrP signalling 84 
disorder», (iPPSD). This terminology: 1) defines the common mechanism 85 
responsible for all diseases, 2) does not require a confirmed genetic 86 
defect, 3) avoids ambiguous terms like “pseudo”, 4) eliminates the 87 
clinical or molecular overlap between diseases. We believe that the use 88 
of this nomenclature and classification will facilitate the development of 89 
rationale and comprehensive international guidelines for the diagnosis 90 
and treatment of iPPSDs. 91 
  92 
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Introduction 93 
 94 
Pseudohypoparathyroidism (PHP) encompasses a group of rare, related, highly 95 
heterogeneous and deeply impairing disorders characterized by end-organ 96 
resistance to the action of parathyroid hormone (PTH) and in most instances 97 
associated with a demonstrated (epi)genetic component (1–3). PHP is 98 
historically the first hormone resistance syndrome described by Fuller Albright 99 
and colleagues in 1942 (4).  100 
 101 
A better understanding of the PHP pathophysiology followed the identification 102 
of the PTH receptor (PTH1R) and its signal transduction pathway (Figure 1) 103 
(5,6). PTH1R, through its activation by two ligands, the PTH and the PTH related 104 
peptide (PTHrP), regulates skeletal development, bone turnover and mineral 105 
ion homeostasis. In the kidney, binding of PTH to PTH1R stimulates the 106 
production of 1,25 dihydroxy vitamin D3, and inhibits phosphate reabsorption 107 
in the proximal tubule, while it increases calcium reabsorption in the distal 108 
nephron. In the growth plate, PTHrP promotes endochondral ossification, 109 
through the binding to PTH1R (7).  110 
 111 
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The Blomstrand chondrodysplasia (OMIM # 215045), a lethal form of dwarfism 112 
(8), was the first disorder associated with biallelic loss-of-function mutations of 113 
the PTH1R gene (9). Subsequently, one report has described a milder 114 
phenotype in living children affected with Eiken disease (OMIM # 600002), 115 
short stature, elevated PTH and mutations of PTH1R (10,11). 116 
A defect in the response of the proximal renal tubule to PTH is the hallmark of 117 
all forms of PHP. It manifests as hypocalcemia, hyperphosphatemia and 118 
elevated circulating levels of PTH in the absence of vitamin D deficiency 119 
(5,7,12). 120 
PTH receptor couples with the stimulatory G protein (Gsa), leading to cAMP 121 
formation. Renal tubular response to exogenously administered PTH through 122 
measurement of serum and urinary cAMP levels, permits the differentiation of 123 
PHP type 1 (PHP1), in which a blunted cAMP response is observed, from PHP 124 
type 2 (PHP2), where cAMP increase is conserved but the phosphaturic 125 
response is deficient (13). To date, only a handful of PHP2 cases have been 126 
reported, and the molecular defect responsible for this variant is still unknown. 127 
It has also been hypothesized that PHP2 could either be an acquired defect 128 
secondary to vitamin D deficiency (14), as calcium and vitamin D 129 
supplementation resulted in normalization of the phosphaturic response to 130 
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PTH in some patients (14,15) or due to defects downstream the Gsa protein, as 131 
seen in patients with acrodysostosis type 1 (ACRDYS1) (16). 132 
In 1980, deficiency in the Gsa protein activity in erythrocytes extracted from 133 
patients affected with PHP1 was demonstrated in vitro (17,18). For years, this 134 
bioassay allowed the diagnosis of PHP, and contributed to PHP subclassification 135 
(see below).  136 
 137 
PHP type 1 (PHP1) is further subdivided based on the presence (PHP1A and 138 
PHP1C; OMIM #103580 and #612462, respectively) (6,17–19) or absence 139 
(PHP1B; OMIM #603233) (6,20) of Albright Hereditary Osteodystrophy (AHO) 140 
(Table 1). AHO is a clinical entity initially described together with PHP in 1942, 141 
which encompasses heterogeneous clinical findings such as brachydactyly, 142 
rounded face, short stature, stocky build and subcutaneous ossifications 143 
(4,21,22). Additional features that may not directly relate to AHO, yet 144 
extensively associated with PHP1A individuals, include obesity, varying degrees 145 
of intellectual disability and resistance to several hormones, including TSH, 146 
GHRH and calcitonin (23–28) . The subcategory of PHP1C has all the 147 
characteristics of PHP1A, except that Gsa activity in erythrocytes was found 148 
comparable to controls (29,30). 149 
 150 
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Interestingly, patients showing the physical features of AHO without any 151 
evidence of PTH resistance were also described by Albright and colleagues ten 152 
years after their first report of PHP (21). This new syndrome, named pseudo-153 
pseudohypoparathyroidism (PPHP; OMIM #612463) may be present either in 154 
kindreds with PHP or as an isolated defect. It is possible that the “bone 155 
phenotype” observed in AHO is largely mediated by the resistance to PTHrP at 156 
the growth plate during fetal and post-natal growth (31). 157 
 158 
In 1990 the first heterozygous inactivating mutation in the gene coding for Gsa 159 
(GNAS), responsible for PHP1A, was described (32). Since then, several Gsa-160 
coding mutations have been identified in all of its 13 exons with different 161 
frequency, with a detection rate of about 70% (33–39). Cases of deletions of 162 
20q, including part or the whole GNAS gene, and an inversion at GNAS have 163 
been recently reported (40–44). Remarkably, similar mutations when 164 
paternally inherited, or occurring de novo on the paternal allele of GNAS may 165 
lead to PPHP or to Progressive Osseous Heteroplasia (POH, OMIM #166350), a 166 
disorder characterized by heterotopic ossifications expanding into deep 167 
muscles and connective tissues (45,46). 168 
 169 
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GNAS is a locus encoding several transcripts through alternative splicing. In 170 
most tissues, except for Gsa, the GNAS transcripts are of monoallelic origin due 171 
to the control of their expression by parent-specific differentially methylated 172 
regions (DMRs) (Figure 2) (47). In thyroid, pituitary gland and most likely in the 173 
proximal tubule (36), Gsa is predominantly expressed from the maternal allele 174 
through a yet unexplained mechanism (48,49). In the early 2000, the molecular 175 
defect of PHP1B was characterized. The most consistent defect common to all 176 
PHP1B patients is a paternal-specific pattern of cytosine methylation within the 177 
maternal GNAS A/B: transcriptional start site (TSS)-DMR (GNAS A/B:TSS-DMR; 178 
previously known as exon A/B or 1A) which could lead to a decreased 179 
expression of Gsa in the renal proximal tubules, hence PTH resistance (50). 180 
Fifteen to 20% of the PHP1B cases present familial history with an autosomal 181 
dominant mode of inheritance (AD-PHP1B) through the maternal lineage. Most 182 
AD-PHP1B show loss of imprinting (LOI) limited to the GNAS A/B:TSS-DMR 183 
(more precisely a loss of methylation [LOM]) associated with deletions on the 184 
maternal allele of cis-acting control elements within STX16 or NESP55 (51–55), 185 
although other maternally inherited deletions have been identified affecting all 186 
four DMRs (GNAS-NESP:TSS-DMR, GNAS-AS1:TSS-DMR, GNAS-XL:Ex1-DMR and 187 
GNAS A/B:TSS-DMR) (56–58). 188 
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The remaining cases of PHP1B are sporadic. They present with broad LOI at 189 
GNAS, including the GNAS A/B:TSS-DMR. The molecular basis of this broad LOI 190 
is yet to be identified, with an exception of less than 10% of the patients who 191 
are affected by paternal complete or segmental uniparental disomy (UPD) of 192 
the chromosome 20, comprising the GNAS locus (59–63). 193 
 194 
To summarize, the existing classification of PHP (Table 1) is based on the 195 
following criteria, 1-presence or absence of AHO differentiates PHP1A/PHP1C 196 
from PHP1B, 2-presence or absence of hormonal resistance differentiates PHP1 197 
from PPHP, 3-in vivo response to exogenous PTH as for nephrogenic cAMP 198 
synthesis and phosphaturia seperates PHP1 from PHP2, and 4-in vitro assay 199 
measuring the Gsa protein activity from erythrocyte membranes, differentiates 200 
between PHP1A and PHP1C.  201 
 202 
As described above, the existing PHP classification does not include molecular 203 
defect as a criterion and fails to stratify PHP and AHO as well as include 204 
conditions such as acrodysostosis, POH and PTH1R-related chondrodysplasia. In 205 
this manuscript, we therefore propose to review the rationale of this 206 
nomenclature and recommend a novel classification for disorders impairing the 207 
PTH/PTHrP signalling pathway.   208 
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Methodology 209 
 210 
The EuroPHP network met on three different occasions (October 2014, May 211 
2015, November 2015) to discuss and agree on a novel classification. The aims 212 
of these meetings were 1- to identify the limitations in the current PHP 213 
classification, 2- to formulate mandatory criteria for the new classification, 3- 214 
to propose a comprehensive definition gathering all the disorders, 4- to analyse 215 
the classifications used in other genetic/epigenetic conditions, 5- to generate a 216 
novel classification. The methodology comprised of a thorough review of the 217 
current literature to facilitate comparison and form basis for the proposal of a 218 
new classification.  219 
 220 
We have carefully considered a series of classifications proposed for various 221 
rare genetic/epigenetic disorders, including the reporting manuscripts that 222 
were taken into consideration for the design of a novel classification 223 
(summarized in Table 2). In brief, methodologies were similar. A group of 224 
experts in the field identified the deficiencies in the existing 225 
classification/terminology and the need for an update. Subsequently 226 
agreement on a novel terminology and classification was reached and reported 227 
(64–70).   228 
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Challenges and limitations of the current classification 229 
Recent clinical and molecular data gathered for these complex disorders have 230 
questioned the distinction of the different PHP and AHO subtypes in the 231 
existing classification (Table 1). We have selected the following limits of the 232 
current classification. 233 
1- In a subset of patients with PHP1A and varying degree of AHO, LOI of GNAS 234 
identical to that of PHP1B has been reported, suggesting a molecular and 235 
clinical overlap between the two subtypes (71); further confirmed (72–75).  236 
2- PHP1B patients present with a moderate reduction of Gsa activity in 237 
erythrocyte membranes, reminiscent -yet less severe- to that observed in 238 
patients with PHP1A and PPHP (76). 239 
3- Recently, mild resistance to PTH was described in patients affected with 240 
PPHP, carrying a paternal GNAS mutation (77), showing that the hormonal 241 
resistance is not only associated with maternally inherited GNAS mutations.  242 
4- Different molecular defects have been identified in patients with PHP1C, i.e. 243 
LOI at GNAS and four loss-of-function mutations in the GNAS carboxyl-terminus 244 
leading to a conserved adenylyl cyclase receptor-independent activation but 245 
disrupted receptor-mediated activation (29,30,78). 246 
6- Paternal GNAS mutations associated with Progressive Osseous Heteroplasia 247 
are usually truncating mutations (79), yet they are identical to those found in 248 
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families with PHP1A and/or PPHP (45). Also noteworthy, is that a fraction of 249 
POH patients exhibits some of the typical AHO features and, conversely, some 250 
PHP1A patients carrying mutations on the maternal allele, present with 251 
progressive deepening heterotopic ossifications. The hypothesis that POH 252 
should be considered as a form of PPHP is therefore debated (80,81). 253 
7- Heterozygous mutations in PRKAR1A -coding for the regulatory subunit of 254 
the protein kinase A (PKA)- and PDE4D -coding for phosphodiesterase type 4- 255 
have been found in patients with acrodysostosis (16,82,83). Acrodysostosis 256 
refers to a heterogeneous group of rare diseases characterized by skeletal 257 
dysplasia and characteristic features, including brachydactyly, facial 258 
dysmorphism and, in some cases, mental retardation (84–88). Acrodysostosis 259 
differs from PHP by more generalized osseous abnormalities (87,89). 260 
Resistance to PTH and/or TSH is present in about 60-70% of acrodysostosis 261 
patients with a PRKAR1A mutation, while, in case of a PDE4D mutation, such 262 
hormone resistances are found only in a smaller subset of 10-20%. 263 
Interestingly, few patients bearing a PRKAR1A mutation have been described in 264 
patients with a phenotype indistinguishable from PHP1A (90,91). 265 
8- Heterozygous mutations in PDE3A have been identified in patients affected 266 
with hypertension and brachydactyly type E (Hypertension and Brachydactyly 267 
Syndrome (HTNB): OMIM #112410) (92). 268 
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9- Disorders associated with an impaired function of PTH1R, i.e. the Blomstrand 269 
and Eiken skeletal dysplasia, are currently not included in the classification. 270 
 271 
Over the past two decades it became obvious that clinical features such as AHO 272 
or in vitro assays such as Gsa bioactivity fail to differentiate between PHP 273 
subtypes. In addition, mutations of genes different from GNAS have been 274 
shown to lead to PTH and/or PTHrP resistance and GNAS mutations might 275 
trigger diseases different from PHP/PPHP (i.e. POH). These disorders are not 276 
encompassed by the current classification system. 277 
 278 
For all these reasons, different independent studies from the authors of the 279 
present paper, as well as the “EuroPHP network” concluded and agreed that a 280 
uniform terminology is required to create a functional working classification 281 
that reflects the current knowledge of the diseases (29,93,94).  282 
 283 
Terminology 284 
We propose the term of «inactivating PTH/PTHrP signalling disorder», 285 
abbreviated as iPPSD, which encompass all disorders related to this pathway. 286 
We also propose that numbering will allow for both clinical features as well as 287 
molecular and genetic findings to be included. The advantages of this 288 
terminology are as follows: 1- it describes the common mechanism responsible 289 
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for the diseases, 2- it does not require a confirmed genetic defect, 3- it avoids 290 
the ambiguous term like “pseudo”, 4- it eliminates the clinical or molecular 291 
overlap between diseases and 5- it is flexible to incorporate new evolving 292 
information. 293 
 294 
We recognize that the nomenclature «inactivating PTH/PTHrP signalling 295 
disorder» might be initially difficult for patients and caregivers to remember. It 296 
would therefore be helpful to rely on the abbreviation iPPSD. Equally the 297 
former terms “pseudohypoparathyroidism” and 298 
“pseudopseudohypoparathyroidism” were also long and challenging to use for 299 
communication. PTH/PTHrP specific pathway was deliberately included in the 300 
name of the classification to avoid the misperception with disorders resulting 301 
from the inactivation of G protein-coupled receptors, i.e. inactivating 302 
mutations in the TSH receptor or in the FSH receptor. All nomenclature based 303 
on the cAMP signalling were carefully considered and rejected due to their 304 
generic nature.  305 
 306 
Identification of mandatory criteria for the new classification  307 
Basis for the newly proposed classification of iPPSD are: 308 
• To provide patients with an unambiguous diagnosis; 309 
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• To base nomenclature on pathophysiology, i.e. the 310 
PTH1R/Gsa/cAMP/PKA pathway, and a standardized diagnostic 311 
pathway; 312 
• To formulate basis to develop new therapeutic approaches; 313 
• To be sufficiently flexible and adaptable to include emerging clinical 314 
and molecular information; 315 
• To be simple and usable for the caregivers. 316 
 317 
It is therefore of significant importance to define the category of iPPSD a 318 
patient belongs to, based on the characterization of clinical/biochemical 319 
criteria, to facilitate a definive diagnosis and, if possible, through molecular 320 
analysis, a more specific denomination within the classification.  321 
 322 
We suggest three key clinical features as major criteria for the diagnosis of 323 
iPPSD. The proposed major criteria have minimum or no overlap with other 324 
conditions due to different mechanisms (see Table 3, especially for the 325 
differential diagnoses).  326 
We also propose a list of minor criteria that are associated with iPPSD. These 327 
are less specific to iPPSD compared to major criteria and can occur in other 328 
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clinical conditions. Therefore, minor criteria need to be combined with one or 329 
more major criteria to establish the diagnosis of iPPSD.  330 
Major criteria 331 
1. PTH resistance 332 
The hallmark of inactivating PTH/PTHrP signalling disorders is the resistance of 333 
the renal proximal tubule to the action of PTH. All genetic defects leading to a 334 
deficient PTH1R signalling in the kidney will therefore be named iPPSD. 335 
2. Ectopic ossifications  336 
Ectopic ossifications are superficial, subcutaneous nodules, defined as ectopic 337 
bone formation in the adipose or dermal tissue. Progressive Osseous 338 
Heterotopic calcifications often begin in the dermal and subcutaneous tissues 339 
and later progress to the deeper tissues, such as muscles and tendons. In 340 
children, ectopic ossifications are highly suggestive of an inactivating GNAS 341 
mutation, i.e. iPPSD.  342 
3. Brachydactyly 343 
Brachydactyly refers to shortening of fingers, toes or both. Brachydactyly type 344 
E (BDE, OMIM #113300) encompasses variable shortening of the 345 
metacarpals/metatarsals, often with the involvement of phalanges (see Figure 346 
3). It can either present in isolation or as part of a genetic disorder, most of 347 
which are included among iPPSD (95).  348 
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Brachydactyly can be challenging to identify in early childhood, and tends to 349 
become more evident during early puberty. Brachydactyly can be overlooked 350 
when all bones are short as in acrodysostosis since early childhood. 351 
While PTH resistance and ectopic ossifications are considered major criteria for 352 
iPPSD, brachydactyly is less specific and should therefore be combined with at 353 
least one major or two minor criteria to trigger the diagnosis of iPPSD. 354 
Minor criteria 355 
1. Thyroid Stimulating Hormone (TSH) resistance 356 
In iPPSD, TSH resistance is often mild and characterized by elevated TSH levels 357 
associated with free thyroxine (T4) levels in a normal or low-normal reference 358 
range. This occurs in the absence of goitre and markers of autoimmune disease 359 
(26,27). TSH resistance can sometimes be the first detected sign of iPPSD, 360 
especially in countries where screening for congenital hypothyroidism is 361 
routinely performed (96).  362 
2. Other hormone resistances  363 
Very few other hormone resistances have been demonstrated so far. 364 
Resistance to growth hormone releasing hormone (GHRH), leading to growth 365 
hormone deficiency, is the most frequent additional resistance found in PHP1A, 366 
affecting as many as 60% of patients (97–99). Calcitonin resistance has been 367 
described without clinical features in patients affected with PHP1A (27). 368 
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Elevated follicular stimulating hormone (FSH) and luteinizing hormone (LH) 369 
levels were reported both by us and Namnoum et al (78,100). Glucagon and 370 
epinephrine resistances were demonstrated in patients with features of PHP 371 
and low Gsa bioactivity through in vivo testing (6,101).  372 
3. Motor and cognitive retardation or impairment  373 
Psychomotor and cognitive alterations have been described in about 40 to 70% 374 
of the patients with a maternal coding mutation of GNAS (25,34), as well as in 375 
some patients affected with acrodysostosis (83,85,86). Psychiatric 376 
manifestations have also been reported in these patients (102). Patients with 377 
paternal mutations of GNAS or epigenetic modifications of the GNAS DMRs 378 
seem unaffected (25,63). 379 
4. Intra-uterine and post-natal growth retardation 380 
Intra-uterine growth retardation (IUGR) has been frequently observed in both 381 
maternal and paternal inherited inactivating GNAS coding mutations. However, 382 
IUGR is more pronounced in patients harbouring mutations on the paternal 383 
GNAS allele, mainly when affecting GNAS exon 2-13 mutations, compared to 384 
patients with GNAS exon 1/intron 1 mutations (103). IUGR has also been 385 
described in acrodysostosis with mutations in PRKAR1A or PDE4D, and in 386 
patients with mutations in PDE3A (16,82,90,92). A LOI at the maternal GNAS 387 
A/B: TSS-DMR has been associated with increased intra-uterine growth (104).  388 
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Post-natal growth retardation is a frequent sign in PHP1A and acrodysostosis. 389 
Growth hormone deficiency and premature closure of the epiphysis result in 390 
short stature (16,82,97,105). Growth retardation has also been observed in 391 
PHP1B, although only in exceptional cases (71,74), and in patients with Eiken 392 
dysplasia (10).  393 
5. Obesity/overweight  394 
Obesity or overweight may be the most nonspecific minor sign, however it 395 
occurs very frequently in disorders with an impaired PTH/PTHrP signalling 396 
pathway and may help to differentiate between the different subtypes. Growth 397 
hormone deficiency, impaired lipolytic response of epinephrine (101), or 398 
decreased resting energy expenditure (106) contribute to the development of 399 
obesity in patients with mutations on the maternal allele of GNAS (23,107). 400 
Obesity is also a frequent feature in patients affected with acrodysostosis 401 
(16,90,108). 402 
6. Flat nasal bridge and/or maxillar hypoplasia and/or round face 403 
Elements of facial dysmorphism have been associated with acrodysostosis (flat 404 
nasal bridge and/or maxillar hypoplasia) or with PHP1A (round face) (4,86). 405 
 406 
Diagnosis of iPPSD  407 
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We propose that a minimum of one of the major criteria is mandatory for the 408 
clinical diagnosis of iPPSD. PTH resistance or ectopic ossifications may lead to 409 
the diagnosis of iPPSD with or without the presence of minor criteria. However, 410 
brachydactyly type E (BDE) should be associated with at least one major or two 411 
minor criteria to suggest iPPSD, as it is a common feature of several other 412 
diseases and syndromes (Table 3). 413 
The known molecular causes of PTH/PTHrP signalling disorders are:  414 
• Inactivating mutations of PTH1R; 415 
• Inactivating heterozygous mutations in the coding sequence of GNAS-416 
Gsa; 417 
• Methylation changes of the DMRs of GNAS caused by 418 
-deletions or duplications at ICRs (STX16; NESP; GNAS-AS1); 419 
-paternal UPD of chromosome 20q; 420 
-unknown mechanism(s); 421 
• Heterozygous mutations of PRKAR1A; 422 
• Heterozygous mutations of PDE4D; 423 
• Heterozygous mutations of PDE3A. 424 
 425 
In contrast to the former diagnostic classification based solely on the 426 
phenotype, once iPPSD has been identified (using criteria described Table 3), 427 
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we propose to further subtype iPPSD based on the underlying molecular 428 
(epi)genetic defect. Therefore, the term iPPSD will refer to the pathophysiology 429 
of the PTH/PTHrP signalling abnormalities, while the number will refer to the 430 
underlying molecular mechanism (responsible for the pathology). We have 431 
numbered iPPSD subtypes starting with PTH1R mutations. 432 
 433 
The novel classification of iPPSD 434 
The European PHP-network proposes the following classification (Figure 4):  435 
• iPPSD: clinical/biochemical diagnosis based on the major/minor criteria 436 
as defined above, in the absence of genetic investigation; 437 
• iPPSD1: loss of function mutation in PTH1R ; 438 
• iPPSD2: loss of function mutation in Gsa; 439 
• iPPSD3: methylation change(s) at one or more GNAS DMRs, associated 440 
with or without a genetic (deletion) or cytogenetic (UPD) defect; 441 
• iPPSD4: PRKAR1A mutation; 442 
• iPPSD5: PDE4D mutation; 443 
• iPPSD6: PDE3A mutation; 444 
• iPPSDx: lack of genetic/epigenetic defect identified following molecular 445 
investigation of known genes described above; 446 
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• iPPSDn+1: the identification of a novel gene/molecular defect will lead 447 
to a disease named iPPSD7, then 8 and so on. 448 
 449 
iPPSD3 encompasses all disorders associated with changes in the methylation 450 
patterns of the DMRs of GNAS, including UPD(20)pat and deletion within 451 
STX16, NESP, etc. Of most significance, is the common mechanism shared by 452 
these patients, i.e. the LOM at the GNAS A/B:TSS-DMR. Grouping them under 453 
iPPSD3 highlights this common mechanism. Secondly, we anticipated the 454 
difficulties in integrating the multiplicity of the epigenetic mechanisms within 455 
the classification system as this adds no further diagnostic value. However, the 456 
further specification of the epigenetic defect can remain part of a private 457 
exchange between the molecular laboratory, the patient and his/her physician.  458 
We recommend the use of Arabic numerals to avoid the confusion with letters 459 
(II with the number 11 for example). 460 
 461 
The advantages of this new nomenclature are: 1- it stratifies the disorders into 462 
clusters caused by the same mechanism, 2- it is flexible and open to 463 
accommodate new defects to be discovered in the future and 3- it simplifies 464 
the concept of the overlapping disorders under a single umbrella. 465 
 466 
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This classification however bears some limitations. We deliberately did not 467 
include the parental origin of the genetic/epigenetic defect, although some 468 
iPPSD are imprinting disorders -namely iPPSD2 and iPPSD3- and their 469 
phenotypic expression depends on their parental inheritance. The main reason 470 
behind this being the association of PTH resistance and POH with both 471 
maternal and paternal inactivating GNAS mutations. Therefore, the mechanism 472 
of the two allelic GNAS mutations can be considered alike. However, in daily 473 
practice, the parental origin of the GNAS defect should be considered, 474 
particularly for genetic counselling. In fact, AHO and multiple hormone 475 
resistance including PTH resistance are largely associated with maternal GNAS 476 
coding defects, whereas, isolated AHO and/or POH are more often associated 477 
with paternal GNAS coding defects.  478 
Another limitation of this classification is the inability to sub classify individuals 479 
with a pure clinical suspicion of iPPSD and lack of complete (epi)genetic testing. 480 
While such patients cannot be classified as iPPSDx or with a specific number, 481 
we recommend that they are classified as iPPSD. 482 
The inclusion of the disorders involving the two main ligands of the PTH1R, i.e. 483 
hypoparathyroidism (109) and brachydactyly type E with short stature 484 
(mutations in PTHLH the gene encoding PTHrP (110,111)) to the classification 485 
may be argued. However, we decided to exclude them due to several other 486 
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issues such as, 1- their different biochemical pattern including low levels of PTH 487 
responsible for hypoparathyroidism 2- the dramatic difference in the therapy 488 
of hypoparathyroidism and defects in PTH1R signalling, respectively and 3- the 489 
difference in research goals in the two disease groups. 490 
491 
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Perspectives  492 
We believe that the use of the new nomenclature will facilitate a more 493 
straightforward approach to the diagnosis of iPPSD, increase awareness of the 494 
red-flag signs of PTH resistance, ectopic ossifications and brachydactyly type E. 495 
It would allow for the classification of patients into local catalogues used by the 496 
different healthcare organizations in a more homogenous way, and enable 497 
future observational and research studies in the field. 498 
 499 
We strongly believe that too many denominations for similar diseases and 500 
patients with phenocopies (PHP, PPHP, POH, ACRDYS, TRPS, BDE, AHO) has 501 
diluted and dispersed research advance, adding undue complexity to the 502 
causative mechanism and proved challenging for the experts in building a 503 
global research network in the field.  504 
 505 
Regular use of the classification in daily practice or for scientific purposes will 506 
allow appropriate amendments in the best interest of the patients.  507 
 508 
While producing this novel nomenclature and classification, we have identified 509 
the need to 1) disseminate this alternative classification to be positively 510 
enriched by the clinical and scientific community, 2) validate the major/minor 511 
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criteria in a series of patients affected by different iPPSDs, and 3) develop 512 
international guidelines for the diagnosis and treatment of the iPPSDs in the 513 
near future.  514 
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 538 
Legends for figures 539 
 540 
Figure 1: Schematic transduction of PTH1R/Gsa/cAMP/PKA pathway. 541 
Upon ligand binding (PTH or PTHrP are mentioned on the figure), the receptor 542 
(PTH1R) activates the G protein. Then the Gsa subunit triggers the activation of 543 
the adenylate cyclase leading to cAMP synthesis. cAMP binds to the regulatory 544 
1A subunits (R1A) of the PKA, the most common effector of cAMP.  545 
Upon cAMP binding, the catalytic subunits (Cat) dissociate from the R1A 546 
subunits, and phosphorylate numerous target proteins including CREB (cAMP-547 
responsive binding elements) and the phosphodiesterases (PDEs). CREB 548 
activates the transcription of cAMP responsive genes. Intracellular cAMP is 549 
then deactivated by PDEs, among which are PDE4D and PDE3A.  550 
PTH1R: transmembrane convolutional black line; G protein: trimer α, β, γ; 551 
cAMP: grey diamond; PKA: tetramer R1A (regulatory subunit 1A) and Cat 552 
(catalytic subunit); phosphodiesterases: ovals PDE4D or PDE3A; DNA: scale bar. 553 
 554 
Figure 2: The imprinted human GNAS locus (Hg19-chr20:57,414,795-555 
57,486,250), on chromosome 20, close to the STX16 gene (Hg19-556 
chr20:57,226,309-57,254,5812) (source UCSC, Hg19). The 557 
centromeric/telomeric orientation of the chromosome is indicated. The 558 
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maternal (NESP), paternal (AB, AS and XL) and biallelic (Gsa) transcripts are 559 
depicted as arrows. Maternal and paternal expressed transcripts are drawn 560 
above and below the horizontal line, respectively. Black boxes: coding exons; 561 
grey boxes: non-coding exons; arrows: transcription (direction and parental 562 
origin). The brackets delimit the imprinting control element deletions, which 563 
have been reported. STX16 gene: full brackets: the recurrent STX16 deletion of 564 
3.3kb (38); large dotted brackets: the STX16 deletion of 4.4 kb (39); small 565 
dotted brackets: the STX16 deletion of 29,5kb (42). GNAS locus: full brackets: 566 
the 4.7kb and 4kb deletions removing the NESP exon and exons 3 and 4 of 567 
GNAS-AS1 (40); large dotted brackets: the 4.2kb deletion removing exons 3 and 568 
4 of GNAS-AS1 (43); deletions of 40pb [*] and 33pb [#] in introns of NESP and 569 
GNAS-AS1 (44); small dotted brackets: the NESP and GNAS-AS1 deletion (41). 570 
Mat: maternal ; Pat: paternal ; cen: centromeric ; tel: telomeric. 571 
 572 
Figure 3: Patterns of brachydactyly type E associated with iPPSD.  573 
a-e, brachydactylies associated with coding mutations in the Gsa subunit of the 574 
G protein (iPPSD2). f-g, bone phenotype associated with the loss of imprinting 575 
at the GNAS locus (iPPSD3). h-j, brachydactylies associated with the molecular 576 
defect in PRKAR1A (iPPSD4) and PDE4D (iPPSD5). Note the phenotypic overlap 577 
between a, h, j, and b, c, g, i, respectively. 578 
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 579 
Figure 4:  Schematic representation of the new classification proposed by the 580 
European PHP network.  581 
According to the suggested new classification Blomstrand and Eiken 582 
chondrodysplasia, PHP type 1 & 2, PPHP, AHO, POH and acrodysostosis 583 
clinically/biochemically diagnosed without genetic investigation are named 584 
iPPSD; Blomstrand and Eiken chondrodysplasia due to PTHR1 inactivating 585 
mutations are named iPPSD1; PHP1A, PHP1C, PPHP and POH clinically 586 
diagnosed and characterized by Gsa inactivating mutations are termed iPPSD2; 587 
PHP1B clinically diagnosed and due to methylation changes at the GNAS DMRs 588 
is classified as iPPSD3; in the presence of acrodysostosis type 1 or PRKAR1A 589 
mutations, the disease is classified as iPPSD4. Acrodysostosis type 2 or PDE4D 590 
mutations are termed iPPSD5; PDE3A mutations are categorized as iPPSD6; 591 
patients lacking genetic or epigenetic defects at the known genes fall under the 592 
category of iPPSDx; any newly discovered genetic/molecular defects will be 593 
labelled as iPPSDn+1.  594 
 595 
  596 
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Table 1: Former classification of PHP along with the other disorders affecting the PTH/PTHrP signalling pathway; note the overlap of phenotypes and 
molecular defects of the patients. Diseases included in the former classification are PHP1A, PHP1B, PHP1C and PPHP. 
 PHP1A PHP1C PHP1B 
Clinical 
presentation 
AHO AHO No AHO AHO in some 
patients 
(brachydactyly, 
subcutaneous 
ossification) 
and/or obesity 
AHO in very few 
patients 
Mental retardation 
reported in 2 patients, 
lambdoid synostosis, 
early-onset obesity, 
macrocephaly 
BWS  No AHO 
Obesity Obesity No obesity   Obesity may be 
present 
  Obesity no obesity 
Cognitive 
impairment 
Cognitive 
impairment 
No Cognitive 
impairment 
          
Subcutaneous 
ossifications 
Subcutaneous 
ossifications 
            
Hormone 
resistance 
Resistance to PTH, 
TSH, GHRH, 
calcitonin, 
epinephrine, 
glucagon and 
gonadotropins  
Resistance to 
PTH, TSH, 
epinephrine and 
gonadotropins 
PTH resistance PTH resistance,  
± TSH resistance 
PTH resistance,  ± 
TSH resistance 
PTH resistance,  ± TSH 
resistance 
PTH 
resistance 
PTH 
resistance,  ± 
TSH 
resistance 
In vitro 
activity of 
Gsa 
Significantly below 
controls 
Similar to controls Similar to 
controls 
Mildy decreased 
when compared 
to controls 
Mildy decreased 
when compared to 
controls 
    Similar to 
controls 
LOI at the 
GNAS DMRs 
      LOM at the 
GNAS A/B:TSS-
DMR 
Broad LOI  Broad LOI  Broad LOI  Broad LOI  
Genetic 
lesion 
Heterozygous 
mutation in the 
coding sequence of 
GNAS (maternal 
allele) 
Heterozygous 
mutation in the 
coding sequence 
of GNAS 
(p.E392K, 
p.E392X, p.L388R 
and p.Y391X, all in 
exon 13) (maternal 
allele) 
Heterozygous 
mutation in the 
coding 
sequence of 
GNAS 
(p.Ile382del) 
(maternal allele) 
Recurrent 3-kb 
STX16 deletion 
or 4.2-kb deletion 
of STX16 
unknown UPD(20)pat including GNAS MLID Maternal 
deletion of 
NESP and/or AS 
or Duplication 
of GNAS 
 References (32–39) (29,30,78)  (112) (50–52,113) (50,51,63,74)  (59–63) (114)  (53,54,58,115)  
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PPHP POH 
2q37.3 
Deletion 
Syndrome 
PHP2 Acrodysostosis 
Blomstrand 
dysplasia 
Eiken 
disease 
Clinical 
presentation 
AHO AHO Subcutaneous 
ossifications 
AHO No AHO Severe AHO AHO Severe 
AHO 
Lethal 
dwarfism 
Epiphyseal 
dysplasia 
Subcutaneous 
ossifications 
Subcutaneo
us 
ossifications 
 Cognitive 
impairment 
Hypocalc
emia, 
osteomal
acia 
Cognitive 
impairment in 
some patients 
  Hypertensi
on 
  Short stature 
Hormone 
resistance 
No Mild No No PTH 
resistance 
PTH 
resistance, 
and TSH in 
some patients  
PTH 
resistance, 
and TSH in 
some 
patients  
No   Elevated 
PTH in one 
patient 
In vitro 
activity of 
Gsa 
Significantly 
below controls 
Significantly 
below 
controls 
                
LOI at the 
GNAS DMRs 
                    
Genetic 
lesion 
Heterozygous 
mutation in the 
coding 
sequence of 
GNAS 
(paternal allele) 
Heterozygou
s mutation in 
the coding 
sequence of 
GNAS 
(paternal 
allele) 
Heterozygous 
mutation in 
the coding 
sequence of 
GNAS 
(paternal 
allele) or no 
mutation 
identified 
Deletion of 
the 2q37.3 
chromosomal 
region 
including 
HDAC4 
None Heterozygous 
mutation in the 
coding 
sequence of 
PRKAR1A or 
PDE4D 
Heterozygo
us mutation 
in the 
coding 
sequence 
of 
PRKAR1A 
Heterozyg
ous 
mutation in 
the coding 
sequence 
of PDE3A 
Biallelic 
inactivating 
mutation in 
the coding 
sequence of 
PTH1R 
Biallelic 
inactivating 
mutation in 
the coding 
sequence of 
PTH1R 
 References 
(34,36,44,100) (77) (39,45,46,79,8
0) 
(116) (14) (16,82,90,91,1
17–120) 
(90,91) (92) (9,11)   (10) 
 
Legend: PHP, pseudohypoparathyroidism; PPHP, Pseudopseudohypoparathyroidism; AHO, Albright’s hereditary osteodystrophy; BWS: Beckwith-
Wiedemann syndrome; MLID: multilocus imprinting defect; NA, not available. 
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Table 2: Non exhaustive review of classifications used in other conditions 
 
  
Methodology used to 
build the classification 
Mode of classification Advantages Limitations 
Primary 
Immunodeficiency 
Diseases (69) 
2-days meeting Groups of diseases according to the 
most fundamental defect 
Presented as a table format 
Allows a practical clinical 
framework for PID 
diagnosis 
The complexities of these 
conditions cannot easily be 
captured in the limited table 
format 
Skeletal dysplasia (66) Meeting, extensive review 
of the literature, and 
circulation of drafts of the 
manuscript 
Groups of diseases defined by 
molecular, biochemical and/or 
radiographic criteria 
Disorders are caused by 
disturbances in related 
metabolic pathways or gene 
networks, Sheer number of 
conditions included 
The “hybrid” nature of the 
classification, not clinical, not 
molecular 
Autosomal dominant 
tubule interstitial kidney 
disease (67) 
Meeting, agreement on the 
manuscript 
Agreement on a novel name: 
ADTKD 
Provide information on 
the disease 
Use in communication with 
patients may not be easy 
Classification based on the 
underlying genetic defect: ADTKD-
gene 
Endocrine diseases (68) Literature review Groups of diseases by organ     
Diabetes mellitus 
(MODY) (70) 
Meetings, agreement on 
the manuscript 
Groups of diabetes by diseases’ 
mechanism 
Provide information on 
the disease mechanism 
Very large groups of disease 
(type 2 diabetes for example) 
Allow numbering of new 
diabetes after identification 
of new genes for MODY 
(MODY1, MODY2, MODY3, 
MODY4, 5) 
Osteogenesis 
Imperfecta (64) 
Literature review Phenotypes on evolution, radiology, 
clinics and genetics 
Provide information on the 
disease mechanism and 
genetics 
Confusing as one causing gene 
may be in different categories 
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Table 3: Definition of major and minor criteria for iPPSD and differential diagnoses 
  Assessment  Differential diagnosis References 
I. MAJOR 
CRITERIA 
1. PTH resistance Ionized calcium, total calcium 
Phosphate 
Magnesium 
PTH 
Vitamin D (25OHD) 
Creatinine 
Urinary calcium 
Urinary phosphate 
PTH infusion test in challenging cases  
Normocalcemic hyperparathyroidism 
Renal failure 
Vitamin D deficiency or any kind of secondary hyperparathyroidism 
(16) 
2. Ectopic ossification  Detailed physical exam 
X-rays 
Fibrodysplasia Ossificans Progressiva (FOP, OMIM# 135100), Post-
traumatic Osteoma Cutis 
  
3. Brachydactyly type 
E (comprises the IV) 
Clinical inspection (fist), Hand and feet X-rays Turner syndrome, Tricho-rhino-phalangeal syndrome (TRPS), TRPS I, 
(OMIM#190350), TRPS-II (OMIM#150230) and TRPS-III, 
(OMIM#190351) 
  
II. MINOR 
CRITERIA 
1. TSH resistance TSH, T4l, Antibodies, Imaging
1
 Mutations in the TSH receptor (26,27) 
2. Other hormonal 
resistances 
IGF-1 (GH stimulation test if necessary), Calcitonin, 
LH, FSH, GnRH test 
  (2,27,78,98–
101) 
3. Motor and cognitive 
retardation or 
impairment 
Computed tomography scan and/or MRI of the 
brain, Psychopathological rating scales adjusted 
for age 
  (24,25,34,85,
86,102,116,1
17) 
4. Intrauterine and 
postnatal growth 
retardation 
IUGR: Gestational age, birth weight, birth length, 
head circumference, comparison to reference 
charts; Post-natal growth: Growth charts, X-ray of 
the left hand for determination of the bone age 
  (16,40,92,10
3,104,121) 
5. Obesity/overweight Weight SDS, BMI percentile, BMI z-score   (23,105,106) 
6. Flat nasal bridge 
and/or maxillar 
hypoplasia and/or 
round face 
Clinical inspection   (4,84,86,90) 
iPPSD 
CLINICAL 
DIAGNOSIS 
a) Presence of one major criteria, either number 1 or 2;  
b) Presence of major criteria number 3 and at least 2 minor criteria
2
 
 
                                                      
1 US in adults with hypothyroidism and no evidence for autoimmunity; thyroid imaging through thyroid scintigraphy and US in neonates 
diagnosed through screening for congenital hypothyroidism. 
2 Minor criteria are nonspecific (obesity/cognitive impairment); for instance, the association of BDE + obesity or BDE + cognitive impairment 
would not be relevant for our classification. By raising the number of minor criteria from 1 to 2, we will reduce the risk of overdiagnosing 
patients with iPPSD. 
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  4
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